ClearPoint Neuro Inc.

ClearPoint Neuro Inc.

NNASDAQ:CLPT
8.30
USD
-0.18
(-2.12%)
-1.21EPS
391.35MMarket Cap
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.75
2.43
2.44
2.09
0.95
0.67
0.85
0.81
0.79
0.85
0.97
1.16
1.31
1.52
Basic EPS, GAAP
-4.95
-3.06
-4.48
-2.93
-0.93
-0.56
-0.42
-0.43
-0.69
-0.68
-0.9
-0.7
-0.9
-1.21
Free Cash Flow per Basic Share
-5.56
-4.93
-4.62
-2.15
-0.78
-0.43
-0.23
-0.52
-0.62
-0.72
-0.6
-0.34
-0.86
-1.11
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-4.67
-0.05
-0.87
-0.21
0.55
0.14
0.3
0.14
2.06
1.5
0.86
0.92
0.95
0.85
Tangible Book Value per Share
-4.67
-0.05
-0.87
-0.21
0.55
0.14
0.3
0.12
2.05
1.46
0.82
0.92
0.23
0.23
Basic Weighted Avg Shares
1
1
2
3
8
11
13
16
21
24
25
27
28
30
Sales/Revenue/Turnover
4
4
5
6
7
7
11
13
16
21
24
31
37
45
Operating Margin (%)
-190.17
-267.98
-168.07
-130.25
-85.86
-71.37
-40.96
-48.48
-82.05
-79.47
-93.7
-62.87
-65.36
-70.56
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
2
2
5
Net Income, GAAP
-7
-5
-8
-8
-7
-6
-6
-7
-14
-16
-22
-19
-26
-36
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-180.29
-125.53
-183.91
-140.36
-97.12
-83.82
-49.39
-52.86
-88.41
-79.97
-92.21
-60.25
-69.08
-79.43
Working Capital
-4
7
1
3
8
5
7
22
57
44
29
23
53
57
LT Debt
4
8
4
4
3
3
2
24
12
11
14
3
58
74
Total Equity
-7
- -
-2
-1
6
2
5
2
49
37
21
25
28
27
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
-167.95
-181.73
-194.8
-56.33
-38.37
-76.09
-81.24
-95.64
-167.52

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
50
50
51
LT Finance Leases
14
14
23
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
31
32
Market Capitalization
273
544
391

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
55
49
67
Cash, Cash Equivalents & STI
36
29
46
Accounts Receivable, Net
9
8
8
Inventories
9
9
10
Total Current Liabilities
9
10
10
Payables & Accruals
4
4
4
ST Debt
- -
- -
- -
Deferred Revenue
2
2
2

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
106.42%
383.15%
10.36%
Free Cash Flow
28.96%
40.51%
165.01%
Net Income, GAAP
16.42%
36.32%
35.03%
Sales/Revenue/Turnover
23.86%
23.7%
17.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8
8
8
8
31
2025
8
9
9
10
37
2026
12
11
12
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.16
-0.16
-0.18
-0.2
-0.7
2025
-0.22
-0.21
-0.21
-0.27
-0.9
2026
-0.32
-0.38
-0.24
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Joseph Michael Burnett
Full Time Employees
172
Sector
Health technology
Industry
Medical specialties
Address
120 S. Sierra Avenue Solana Beach CA United States 92075
IPO Date
Jul 3, 2019
Business
ClearPoint Neuro, Inc. (Nasdaq:CLPT) is a global device, cell, and gene therapy-enabling company offering precise navigation and delivery solutions to the brain and spine. Founded in 1998 and headquartered in Solana Beach, California, the company provides the ClearPoint Neuro Navigation System, an FDA-cleared and CE-marked integrated platform for minimally invasive procedures including deep brain stimulation electrode insertion, biopsy needle placement, laser catheter ablation via the ClearPoint PRISM Laser Therapy System, and pharmaceutical infusions; SmartFrame OR for stereotactic neurosurgery; ClearPoint Maestro Brain Model for procedural planning; ClearPoint Array Platform; associated disposables and software; and preclinical development services through ClearPoint Advanced Laboratories (CAL), including GLP studies for central nervous system (CNS) drug delivery. It serves neurosurgeons, biopharma partners conducting over 60 gene and cell therapy programs, research centers, and patients targeting complex neurological disorders such as tumors, epilepsy, and Parkinson's disease; operations span healthcare and research facilities in North America, Europe, Asia, South America, with regulatory approvals in 34 countries including recent expansions in Canada, Hong Kong, and Taiwan. Recent developments include FDA 510(k) clearance in 2025 for ClearPoint PRISM compatibility with 1.5T MRI scanners, operational launch of the CAL facility in Torrey Pines, California, prototype demonstration of a Robotic Neuro-Navigation System integrating KUKA LBR Med arm for MRI, CT, and robotic workflows, a note financing arrangement with Oberland Capital providing up to $110 million including $30 million initially funded in 2025, and completion of the acquisition of IRRAS Holdings, Inc. on November 20, 2025 for $5 million cash and 1.325 million shares, adding the IRRAflow active fluid-exchange system for intracranial hemorrhage management, over 50 customers, and expanded commercial scale in neurocritical care.

Company News

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

  • ClearPoint Neuro: Momentum Building Across The Business

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

  • What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call

  • ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates

  • ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

  • ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT

  • CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law

  • CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law

  • Cedar Grove Capital Q3 2026 Portfolio Update

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT